Insilico Medicine AI-designed TNIK inhibitor rentosertib (INS018_055)
Model ● Covered in 0 stories + Follow
This profile is built automatically from TLDRocket coverage.
Specifications
No specifications recorded yet.
Model ● Covered in 0 stories + Follow
This profile is built automatically from TLDRocket coverage.
No specifications recorded yet.
The daily briefing
TLDRocket reads all relevant sources, removes duplicate coverage, and summarises the day in two minutes. Follow companies and topics for alerts, or get the briefing in Slack. Free, no spam, unsubscribe anytime.
TLDRocket
18 September 2026
The biggest signal today wasn’t a new model—it was money moving to the infrastructure that makes models practical. Crusoe, OpenAI’s Stargate partner, raised $3.9 billion in a Series F that pushes its post-money valuation to $30.9 billion, up from about $10 billion after its roughly year-earlier Series E. The implication is simple: compute is still the scarce input, and data-center scale remains where value concentrates. Crusoe says the cash will fund projects like Abilene and expand its AI data-center and cloud offerings, with board changes and “potential IPO discussions” adding to the sense that this is moving from high-growth story to public-market candidate.
Read the full briefing →